- Datum15.01.2025
- Uhrzeit15:00 - 15:30 Uhr
- Veranstalter
stock3
Thomas May
Moderator
Arcellx Inc Aktie
Verkaufen
Kaufen
Arcellx Inc Chart
stock3 TerminalDu willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnen
Arcellx Inc Realtime-Kurs
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| Nasdaq | VK | |||||
| Nasdaq Basic | VK | |||||
| Cboe BZX | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
0,56 %
Intraday
-9,86 %
1 Woche
-16,48 %
1 Monat
36,11 %
Seit Jahresbeginn
40,28 %
1 Jahr
Wikifolio
Passender Service zu Arcellx Inc
Webinar zu Arcellx Inc
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)47,880-107,370
- Jahrestief / Hoch ($)47,880-107,370
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Arcellx Inc
Keine Dividenden verfügbar
Termine von Arcellx Inc
Keine aktuellen Termine
Beschreibung
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
